HOTLINE: Effective November 15, 2021

New Test **3004232** **Hemophilia A (*F8*) 2 Inversions with Reflex to Sequencing and Reflex to Deletion/Duplication** **F8-COMP**

Patient History for Hemophilia A or B Gene Testing

Additional Technical Information

Methodology: Inverse Polymerase Chain Reaction/Massively Parallel Sequencing/Multiplex Ligation-dependent Probe Amplification
Performed: Varies
Reported: Within 2 weeks, if reflexed add 3-6 weeks

Specimen Required: Collect: Lavender or Pink (EDTA) or Yellow (ACD Solution A or B).
Specimen Preparation: Transport 3 mL whole blood. (Min: 3 mL)
Storage/Transport Temperature: Refrigerated.
Unacceptable Conditions: Serum or plasma; grossly hemolyzed or frozen specimens. Saliva. Buccal brush or swab, FFPE tissue, DNA.
Stability (collection to initiation of testing): Ambient: 72 hours; Refrigerated: 1 week; Frozen: Unacceptable

Reference Interval: By report.

Interpretive Data: Refer to report.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Counseling and informed consent are recommended for genetic testing. Consent forms are available online.

Note: *F8* inversion testing is performed on all specimens. If inversion testing does not explain the clinical scenario, then *F8* gene sequencing will be added. If sequencing does not explain the clinical scenario, then deletion/duplication testing will be added. Additional charges apply.

CPT Code(s): 81403; if reflexed to NGS, add 81407; if reflexed to Del/Dup, add 81406

New York DOH approval pending. Call for status update.

HOTLINE NOTE: Refer to the Test Mix Addendum for interface build information.